Latest news with #giantcellarteritis
Bloomberg
14 hours ago
- Health
- Bloomberg
Novartis Blockbuster Antibody Drug Fails in Late-Stage Trial
Novartis AG 's drug Cosentyx failed in a late-stage study of patients suffering from inflammation in their blood vessels, a blow to the Swiss company's efforts to find new uses for the blockbuster medicine. The therapy, already one of Novartis's top sellers, did not demonstrate statistically significant improvement in adult patients suffering from giant cell arteritis, an ailment that can cause loss of vision and life-threatening aneurysms, according to a statement Thursday. The drug was compared with placebo, with all trial participants also getting a steroid.
Reuters
14 hours ago
- Health
- Reuters
Novartis drug Cosentyx fails late-stage trial for artery disease
ZURICH, July 3 (Reuters) - Novartis (NOVN.S), opens new tab said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), a condition characterised by inflammation of the arteries. The drug failed to show an improvement in sustained remission among patients with newly diagnosed or relapsing GCA, a condition that affects people aged mainly over 50 and can cause vision loss and life threatening aneurysms, Novartis said. "While the Phase III results... did not replicate the positive outcomes observed in the Phase II trial, we remain committed to continuing to drive scientific progress and deepening the understanding of immune-mediated diseases," said Shreeram Aradhye, president of development and chief medical officer at the company.
